Nanjing BIOSON biotech co., Ltd

Biosion is a global biotechnology company focusing on the discovery and clinical development of innovative biologicals for unmet medical needs. Leveraging our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, Biosion is able to undertake a deep discovery of antibody drug candidates with superior properties, multiple differential choices, and diversified clinical applications. Based on its integrated antibody discovery engine and fueled by our corporate motto of "Innovation for Cures", Biosion is committed to bring next generation innovative drugs to patients around the world.

During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.
Jul, 2017
Completed Series A Financing and corporate restructuring, incorporation of Biosion, Inc.
Mar, 2013
Inception of Biosynergics, Inc.
Feb, 2013
Awarded by Nanjing " Entrepreneurial Talents" for a Starup Company